Publications by authors named "Philippe Ronga"

Claim this Profile
R
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer.
Chiara Cremolini, Clara Montagut, Philippe Ronga, Filippo Venturini, Kensei Yamaguchi

Front Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer.
Chris P Pescott, Emmanuelle Boutmy, Michael Batech, Philippe Ronga, Francois-Xavier Lamy

J Comp Eff Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population.
Francois-Xavier Lamy, Michael Batech, Emmanuelle Boutmy, Philippe Ronga, Shaista Salim

J Comp Eff Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.
Sebastian Stintzing, Ilse van Oostrum, Chris P Pescott, Philippe Ronga, Bart Heeg

J Med Econ· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.
Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga

Front Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.
Richard M Goldberg, Clara Montagut, Zev A Wainberg, Philippe Ronga, François Audhuy

ESMO Open· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.
Bernd Tischer, Martina Bilang, Matthias Kraemer, Philippe Ronga, Mario E Lacouture

Support Care Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Wolff Schmiegel, Rodney J Scott, Susan Dooley, Wendy Lewis, Cliff J Meldrum, Philippe Ronga

Mol Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis